Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib in CML
NCT00038597Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2001
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lonafarnib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response Rate. Started Apr 2001; status: completed.
02
Drugs
lonafarnib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00038597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038597.